{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-002466","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.079079+00:00","generated_at":"2026-05-27T11:33:33.422012+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Foghorn Therapeutics receives Nasdaq non-compliance notice over audit committee composition","bullets":["Nasdaq notified Foghorn on Jan 23, 2025 that its audit committee has only two members, violating Listing Rule 5605.","Vacancy follows resignation of director Adam M. Koppel from board and audit committee effective Dec 29, 2024.","Cure period runs until earlier of next annual meeting or Dec 29, 2025; if meeting before June 27, 2025, then by June 27, 2025.","Board intends to appoint a new independent director to fill the audit committee vacancy within the cure period."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-002466","json":"https://secwatch.observer/filing/0001628280-25-002466.json","markdown":"https://secwatch.observer/filing/0001628280-25-002466.md","text":"https://secwatch.observer/filing/0001628280-25-002466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/fhtx-20250123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:33:33.422012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fae198e41a88bc8bd9db191c9b5c338a769a06e1","claim":"Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee.","evidence_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-025087","ticker":"LASE","company_name":"Laser Photonics Corp","filed_at":"2026-05-22T21:27:31+00:00","headline":"Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025087","json":"https://secwatch.observer/filing/0001493152-26-025087.json","markdown":"https://secwatch.observer/filing/0001493152-26-025087.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"received a notice from Nasdaq Listing Qualifications\ndepartment of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q\nfor the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated\nthat the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception\nto allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or\nNovember 16, 2026. A\ncopy of t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm"}},{"accession":"0002001557-26-000118","ticker":"INV","company_name":"Innventure, Inc.","filed_at":"2026-05-19T21:45:13+00:00","headline":"Innventure regains Nasdaq compliance after appointing Bruce Brown to Audit Committee","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002001557-26-000118","json":"https://secwatch.observer/filing/0002001557-26-000118.json","markdown":"https://secwatch.observer/filing/0002001557-26-000118.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/0002001557-26-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/innv-20260515.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"April 30, 2026, following the resignation of Daniel Hennessy from the Company’s Board of Directors (the “Board”) and Audit Committee effective April 29, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/0002001557-26-000118-index.htm"}},{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001213900-26-063575","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-06-01T21:00:15+00:00","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063575","json":"https://secwatch.observer/filing/0001213900-26-063575.json","markdown":"https://secwatch.observer/filing/0001213900-26-063575.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company doe","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001493152-26-026520","ticker":"NUTR","company_name":"NUSATRIP Inc","filed_at":"2026-06-01T11:10:27+00:00","headline":"NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026520","json":"https://secwatch.observer/filing/0001493152-26-026520.json","markdown":"https://secwatch.observer/filing/0001493152-26-026520.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)\nfrom the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s\nnon-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely\nfile its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended\nMarch 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm"}},{"accession":"0001213900-26-063141","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-06-01T11:05:20+00:00","headline":"Twenty One Capital receives NYSE non-compliance notice; audit committee lacks independence; cure due June 5","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063141","json":"https://secwatch.observer/filing/0001213900-26-063141.json","markdown":"https://secwatch.observer/filing/0001213900-26-063141.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/0001213900-26-063141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/ea0292652-8ka1_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"cator\nand website references will be removed when the Company regains compliance with all NYSE quantitative and corporate governance listing\nstandards. The Company expects to appoint, as soon as practicable, an additional member to the audit committee who meets the independence\nrequirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the Listed Company Manual. Forward-Looking Statements Certain statements in this periodic report are “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words indi","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/0001213900-26-063141-index.htm"}},{"accession":"0001213900-26-063100","ticker":"COLA","company_name":"Columbus Acquisition Corp/Cayman Islands","filed_at":"2026-05-30T01:56:47+00:00","headline":"Columbus Acquisition regains compliance with Nasdaq $50M MVLS rule; delisting risk removed","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063100","json":"https://secwatch.observer/filing/0001213900-26-063100.json","markdown":"https://secwatch.observer/filing/0001213900-26-063100.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/0001213900-26-063100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/ea0292674-8k_columbus.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/0001628280-25-002466-index.htm","comparable_excerpt":"May 28, 2026, the Company the Company received a written notice from Nasdaq notifying the Company that the Staff has determined that\nfor the last 10 consecutive business days, from May 13, 2026 to May 27, 2026, the Company’s MVLS has been $50 million or greater.\nAccordingly, the Company has regained compliance with the MVLS Rule and the Staff has indicated that the matter is now closed. 1 SIGNATURES Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized. Columbus\n Acq","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/0001213900-26-063100-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}